The impact of different equine influenza vaccine products and other factors on equine influenza antibody levels in Thoroughbred racehorses

2014 ◽  
Vol 47 (6) ◽  
pp. 662-666 ◽  
Author(s):  
M. Ryan ◽  
S. Gildea ◽  
C. Walsh ◽  
A. Cullinane
Keyword(s):  
Influenza Vaccine ◽  
Equine Influenza ◽  
Thoroughbred Racehorses ◽  
Antibody Levels ◽  
The Impact

scholarly journals Studies with inactivated equine influenza vaccine: 2. Protection against experimental infection with influenza virus A/equine/Newmarket/79 (H3N8)

1983 ◽  
Vol 90 (3) ◽  
pp. 385-396 ◽  
Author(s):  
Jennifer Mumford ◽  
J. M. Wood ◽  
A. M. Scott ◽  
C. Folkers ◽  
G. C. Schild
Keyword(s):  
Influenza Virus ◽  
Influenza Vaccine ◽  
Antibody Responses ◽  
Complete Protection ◽  
Equine Influenza ◽  
Virus Excretion ◽  
Clinical Protection ◽  
Antibody Levels ◽  
H3n8 Virus ◽  
Virus Isolates

SUMMARYForty ponies immunized with inactivated virus vaccine containing A/equine/Miami/63 (H3N8) virus and six unvaccinated, seronegative ponies were experimentally challenged with a representative of recent equine H3N8 virus isolates, A/equine/Newmarket/79. All unvaccinated ponies became infected as judged by virus excretion, febrile responses and antibody responses, but only two of the vaccinated ponies were fully protected. Pre-challenge antibody levels to A/Newmarket/79 virus detected by single radial haemolysis (SRH) correlated well with the degree of clinical protection but the levels required for complete protection (SRH zones > 65 mm2) were high. The importance of these results in relation to conventional vaccination procedures against equine influenza is discussed.

scholarly journals What If the Influenza Vaccine Did Not Offer Such Variable Protection?

2020 ◽  
Vol 222 (7) ◽  
pp. 1138-1144 ◽  
Author(s):  
Sarah M Bartsch ◽  
Elizabeth A Mitgang ◽  
Gail Geller ◽  
Sarah N Cox ◽  
Kelly J O’Shea ◽  
...  
Keyword(s):  
Influenza Vaccine ◽  
Compartment Model ◽  
Medical Costs ◽  
The United States ◽  
Individual Factors ◽  
Policy Makers ◽  
Direct Medical Costs ◽  
Productivity Losses ◽  
Potential Impact ◽  
The Impact

Abstract Background The protection that an influenza vaccine offers can vary significantly from person to person due to differences in immune systems, body types, and other factors. The question, then, is what is the value of efforts to reduce this variability such as making vaccines more personalized and tailored to individuals. Methods We developed a compartment model of the United States to simulate different influenza seasons and the impact of reducing the variability in responses to the influenza vaccine across the population. Results Going from a vaccine that varied in efficacy (0–30%) to one that had a uniform 30% efficacy for everyone averted 16.0–31.2 million cases, $1.9–$3.6 billion in direct medical costs, and $16.1–$42.7 billion in productivity losses. Going from 0–50% in efficacy to just 50% for everyone averted 27.7–38.6 million cases, $3.3–$4.6 billion in direct medical costs, and $28.8–$57.4 billion in productivity losses. Going from 0–70% to 70% averted 33.6–54.1 million cases, $4.0–$6.5 billion in direct medical costs, and $44.8–$64.7 billion in productivity losses. Conclusions This study quantifies for policy makers, funders, and vaccine developers and manufacturers the potential impact of efforts to reduce variability in the protection that influenza vaccines offer (eg, developing vaccines that are more personalized to different individual factors).

scholarly journals Retraction Note: The impact of repeated vaccination on influenza vaccine effectiveness: a systematic review and meta-analysis

BMC Medicine ◽  
2018 ◽  
Vol 16 (1) ◽  
Author(s):  
Lauren C. Ramsay ◽  
Sarah A. Buchan ◽  
Robert G. Stirling ◽  
Benjamin J. Cowling ◽  
Shou Feng ◽  
...  
Keyword(s):  
Systematic Review ◽  
Influenza Vaccine ◽  
Meta Analysis ◽  
Vaccine Effectiveness ◽  
The Impact

scholarly journals Influenza Vaccine Uptake and Associated Factors in Aged Care Facilities

2019 ◽  
Vol 34 (s1) ◽  
pp. s140-s140
Author(s):  
Mohana Kunasekaran ◽  
Mallory Trent ◽  
Elisa Lai ◽  
HaoYi Tan ◽  
Abrar Chughtai ◽  
...  
Keyword(s):  
High Risk ◽  
Influenza Vaccine ◽  
Influenza Vaccination ◽  
Aged Care ◽  
Vaccine Uptake ◽  
Care Staff ◽  
Age Related ◽  
Care Facilities ◽  
Aged Care Facilities ◽  
The Impact

Introduction:Influenza vaccine is recommended for high-risk populations in Australia (including those aged over 65 years) but is less effective in the elderly due to a progressive and predictable age-related decline in immune function, referred to as immunosenescence. Aged care facilities (ACF) are known to be at high risk of explosive outbreaks of influenza (even in highly vaccinated populations) and may reflect a higher intensity of transmission within the closed setting of ACF, as well as lower immunity and immunosenescence in the frail elderly.Methods:To measure the impact of influenza in aged-care staff (ACS) and residents as well as vaccine effectiveness, a prospective observational epidemiological study was conducted in collaboration with an aged-care provider with multiple sites from March to October 2018. Weekly active surveillance on influenza-like symptoms and questionnaires were used to collect data on two groups: ACS and residents. A range of variables was examined against their 2018 influenza vaccination status in statistical analysis.Results:Vaccination rates were high in residents and consistent with other studies. Vaccine rates in aged-care staff were lower and consistent with other studies.Discussion:Residents and relatives are unlikely to change their minds about vaccination from year to year unless there is targeted effort to persuade them to so, and negative perception of the vaccine is likely to persist. Workplace influenza vaccination programs targeted at staff could be an effective method of raising vaccine uptake.

scholarly journals Evaluation of determinants of the serological response to the split-inactivated influenza vaccine

2021 ◽  
Author(s):  
Shaohuan Wu ◽  
Ted M. Ross ◽  
Michael A. Carlock ◽  
Elodie Ghedin ◽  
Hyungwon Choi ◽  
...  
Keyword(s):  
Influenza Vaccine ◽  
Regression Models ◽  
Seasonal Influenza ◽  
Vaccine Dose ◽  
Serological Response ◽  
Linear Regression Models ◽  
Negative Effects ◽  
Categorical Response ◽  
One Year ◽  
The Impact

AbstractThe seasonal influenza vaccine is only effective in half of the vaccinated population. To identify determinants of vaccine efficacy, we used data from >1,300 vaccination events to predict the response to vaccination measured as seroconversion as well as hemagglutination inhibition (HAI) levels one year after. We evaluated the predictive capabilities of age, body mass index (BMI), sex, race, comorbidities, prevaccination history, and baseline HAI titers, as well as vaccination month and vaccine dose in multiple linear regression models. The models predicted the categorical response for >75% of the cases in all subsets with one exception. Prior vaccination, baseline titer level, and age were the strongest determinants on seroconversion, all of which had negative effects. Further, we identified a gender effect in older participants, and an effect of vaccination month. BMI played a surprisingly small role, likely due to its correlation with age. Comorbidities, vaccine dose, and race had negligible effects. Our models can generate a new seroconversion score that is corrected for the impact of these factors which can facilitate future biomarker identification.

scholarly journals COVID-19 convalescent plasma donors: impact of vaccination on antibody levels, breakthrough infections and reinfection rate.

2021 ◽  
Author(s):  
Massimo La Raja ◽  
Monia Pacenti ◽  
Ileana Grimaldi ◽  
Caterina Boldrin ◽  
Margherita Cattai ◽  
...  
Keyword(s):  
Antibody Response ◽  
Antibody Level ◽  
Natural Infection ◽  
Vaccination Campaign ◽  
Reinfection Rate ◽  
Post Vaccination ◽  
Exponential Increase ◽  
The One ◽  
Antibody Levels ◽  
The Impact

From April 2020 through May 2021 in Padova Province 3395 COVID-19 recovered patients were recruited as potential convalescent plasma donors and tested for SARS-CoV-2 antibodies. Since January 2021 COVID-19 vaccination campaign began in Italy, the impact of vaccination on antibody levels and suspect vaccine breakthrough infections in these subjects were investigated. Post-vaccination anti-Sars-Cov-2 antibody level in 54 previously infected subjects had an exponential increase compared to pre-vaccination level regardless of the number of vaccine doses. However after 100 days from vaccination SARS-CoV-2 antibody level tends to decline. Post-vaccination primary infections were detected in 15 cases, with 3 possible breakthrough infections after a full vaccination course. In these cases, antibody response after infection was present but weaker than the one of subjects vaccinated after natural infection. A trend toward stronger antibody response was observed with increasing distance between natural infection and vaccination. Additionally, 2 cases of asymptomatic reinfections are also discussed.

scholarly journals The impact of the 2009 influenza A(H1N1) pandemic on attitudes of healthcare workers toward seasonal influenza vaccination 2010/11

2011 ◽  
Vol 16 (17) ◽  
Author(s):  
C Brandt ◽  
H F Rabenau ◽  
S Bornmann ◽  
R Gottschalk ◽  
S Wicker
Keyword(s):  
Medical Students ◽  
Influenza Vaccine ◽  
Influenza Vaccination ◽  
Healthcare Workers ◽  
Influenza A ◽  
Influenza Season ◽  
University Hospital ◽  
The Public ◽  
Influenza A H1n1 ◽  
The Impact

The emergence of the influenza A(H1N1)2009 virus provided a major challenge to health services around the world. However, vaccination rates for the public and for healthcare workers (HCWs) have remained low. We performed a study to review the reasons put forward by HCWs to refuse immunisation with the pandemic vaccine in 2009/10 and characterise attitudes in the influenza season 2010/11 due to the emergence of influenza A(H1N1)2009. A survey among HCWs and medical students in the clinical phase of their studies was conducted, using an anonymous questionnaire, at a German university hospital during an influenza vaccination campaign. 1,366 of 3,900 HCWs (35.0%) were vaccinated in the 2010/11 influenza season. Of the vaccinated HCWs, 1,323 (96.9%) completed the questionnaire in addition to 322 vaccinated medical students. Of the 1,645 vaccinees who completed the questionnaire, 712 had not been vaccinated against the influenza A(H1N1)2009 virus in the 2009/10 season. The main reason put forward was the objection to the AS03 adjuvants (239/712, 33.6%). Of the HCWs and students surveyed, 270 of 1,645 (16.4%) stated that the pandemic had influenced their attitude towards vaccination in general. Many German HCWs remained unconvinced of the safety of the pandemic (adjuvanted) influenza vaccine. For this reason, effective risk communication should focus on educating the public and HCWs about influenza vaccine safety and the benefits of vaccination.

Sign in / Sign up

Export Citation Format

Share Document